{"url_path":"/sec/slxn/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002739-index.html","accession_number":"0001178913-26-002739","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002739-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":76,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits \n\n \n\n(d) Exhibits\n\n \n\n \n\n \n\n[10.1](exhibit_10-1.htm)\n\n[Form of Inducement\nLetter](exhibit_10-1.htm)\n\n \n\n \n\n[10.2](exhibit_10-2.htm)\n\n[Form of New Warrant](exhibit_10-2.htm)\n\n \n\n \n\n104\n\nCover Page Interactive Data File (formatted in Inline XBRL)\n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report\nto be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nSILEXION THERAPEUTICS CORP\n\n \n\n \n\nDate: May 15, 2026\n\n/s/ Ilan Hadar\n\n \n\nName:\n\nIlan Hadar\n\n \n\nTitle:\n\nChief Executive Officer"}